STAT

Opinion: The policy initiatives Scott Gottlieb championed at the FDA will remain after he departs

The FDA will carry on the policies that Scott Gottlieb worked on and promoted after he steps down as commissioner, says a former agency associate commissioner and longtime FDA watcher.
FDA Commissioner Scott Gottlieb

The resignation of Scott Gottlieb as commissioner of the Food and Drug Administration raises a big question: Will the policies so publicly advocated by Gottlieb continue after his departure?

Gottlieb has been one of the most communications-savvy administrators the government has ever seen. He tweeted virtually every day as @SGottliebFDA not just to tell the Twitterverse what he was doing but to substantively explain complex policies and to advocate for FDA decisions. Many of his tweets were issued on weekends; you almost see Gottlieb sitting in his home writing and transmitting his tweets.

Gottlieb also through official FDA channels, covering virtually

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks